By developing and validating a rapid method detecting the majority of the real-time tumor-specific reactive CD8+ and CD4+ TIL repertoire in vitro, we have addressed a major ongoing issue in cancer immune-monitoring. This evidence concerns the gene CD4 and neoplasm.